You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Multinational nephrology firm Fresenius Medical Care eventually wants as many as 200,000 samples in its registry and aims to sequence 20,000 patients this year.
By extending Terra to the Microsoft Azure cloud, the Broad and Verily Life Sciences hope to facilitate better data sharing, analysis, and reuse.
The company has reached agreements with investors for a direct offering of 2.2 million shares at $1 per share, for gross proceeds of about $2.2 million.
The early-stage company just launched a bioinformatics security service, but it is developing technology to label and manage individual molecules in DNA samples.
Laboratories that purchase PGDx Elio genomic profiling tests will receive access to Qiagen's QCI Interpret One for rapid, evidence-based variant interpretation.
The companies say that the integration of the Nvidia DGX Station A100 will support "real-time analyses" of long-read DNA and RNA sequences.
The partners will use Adaptive's ImmunoSeq T-Map technology to analyze immune response to cancer antigens across AstraZeneca's oncology portfolio.
The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.
The African health technology company 54gene is eager for partnerships with researchers and biopharmaceutical companies alike.
The method, published in Science, pairs in situ sequencing with NGS using barcodes to provide spatial information on DNA sequences inside tissues.
A new partnership between Microsoft, the Broad, and Verily Life Sciences aims to improve collaboration among Terra users worldwide.
The bioinformatics and sequencing firm, formerly known as WuXi NextCode, will develop a population clinicogenomic database to support Emory's research.
The Gene Curation Coalition, led by the Broad Institute, is serving as a clearinghouse of sorts for curated datasets on Mendelian disorders.
The Dutch bioinformatics firm's ImmunoGenomiX technology platform is helping researchers develop therapies for COVID-19 as well as for cancer.
The combined solution will give health systems access to real-time genetics expertise so they can integrate genetic test results into patients' care.
The researchers also examined the contribution of rare variants to inflammatory bowel disease to find a potential targetable pathway.
Early data around an initial composite assay showed it can predict immunooncology drug responses more accurately than tumor mutational burden.
NHGRI has moved the Genotype-Tissue Expression dataset entirely to the cloud in an effort to democratize access to the huge but formerly pricey compendium.
Earlier this year, Novigenix and collaborators were awarded up to €1 million to develop a blood-based multi-omics colorectal cancer assay.
Q2 Solutions will run Adaptive's NGS-based immune cell receptor profiling assay for its pharma and biotech clients, potentially in COVID-19 vaccine trials.
Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.
Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.
Science reports that a Dutch research funding agency is combating a ransomware attack.
In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.